Eiger BioPharmaceuticals Inc (EIGR.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|52||2016||President, Chief Executive Officer, Director|
|58||2016||Chief Financial Officer|
|51||2018||Chief Operating Officer and Executive Medical Officer and Director|
|53||2015||Vice President - Corporate Operations|
|53||2006||Vice President - Clinical Operations|
- UPDATE 2-Eiger to abandon blood pressure drug after trial failure
- BUZZ-Eiger BioPharma: Abandons blood pressure drug after trial failure
- Eiger BioPharma abandons blood pressure drug after failed study
- BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal
- BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln